TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A study published in Nature Medicine links lower levels of the protective protein NRF2 in oligodendrocytes to abnormal myelin, loss of large nerve fibers and faster cognitive decline. Mouse experiments support a role for the pathway, but whether medicines targeting NRF2 can help older adults remains unknown.
Researchers have linked dysfunction in oligodendrocytes—brain cells that maintain the protective myelin coating around nerve fibers—to faster cognitive decline in older adults. In a study published in Nature Medicine, analysis of human brain tissue and experiments in mice connected lower activity of the protein NRF2 in these cells with abnormal myelin and damage to large nerve fibers; the findings point to a possible research target, not a proven treatment.
The study, led by researchers from the University of Edinburgh and the UK Dementia Research Institute, examined participants in the Lothian Birth Cohort 1936, whose cognitive abilities had been tracked from childhood into old age. Between ages 70 and 82, participants completed assessments of memory, information-processing speed and spatial reasoning. Of 1,091 people enrolled, 866 completed additional cognitive testing after age 70. Most experienced some decline, but its rate varied.
Researchers compared those changes with brain tissue collected after death from a subset of participants. Greater cognitive decline was associated with fewer large nerve fibers and an abnormal buildup of myelin, the insulation that helps electrical signals travel along nerve fibers. The tissue findings were associated with the rate of decline over time, rather than with a person’s cognitive test performance at one particular age.
The team found that people with more severe decline had lower NRF2 levels in oligodendrocytes. NRF2 regulates genes involved in cellular defenses and normal function. In mice, researchers reduced NRF2 specifically in oligodendrocytes; the animals developed excess myelin, lost large nerve fibers and showed less improvement on cognitive tasks as they aged. These experiments support a possible causal role in mice, but do not establish that the same process causes human cognitive decline.
A Possible Target in Aging Brains
The findings broaden attention beyond nerve cells themselves to the support cells that maintain the conditions those fibers need to function. If oligodendrocytes become less able to maintain myelin with age, that dysfunction could be one contributor to changes in communication across the brain. The human tissue results show an association, while the mouse work offers experimental evidence that altering NRF2 in these cells can produce similar physical changes.
The NRF2 pathway may also offer a route for future research because medicines that act on it are already used for other neurological conditions, including multiple sclerosis. The researchers suggest those drugs or related approaches could be investigated for age-related decline. However, the study does not show that an existing drug prevents or treats cognitive decline in older adults. Any such use would require clinical testing for benefit and safety in that population.
NRF2 supplement for cognitive health
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Tracking Change Across Decades
The Lothian Birth Cohort’s long-running records allowed researchers to compare cognitive change across years with later findings in brain tissue. That distinction matters: the study focused on how quickly abilities changed, not simply who scored higher or lower at a single assessment. Postmortem tissue was available only for a subset, so the biological findings do not represent every participant in the cohort.
Oligodendrocytes produce and maintain myelin, which supports efficient signaling along nerve fibers. Their usual role is protective, but the report describes evidence that age-related dysfunction may alter that support. The authors also point to existing medicines that affect NRF2 as a reason to investigate the pathway further; that possibility remains a research lead, not a clinical recommendation.
“As the prevalence of cognitive decline is rising with an aging population and no current treatments exist, we are excited about this work as it points to a potential strategy for new therapeutic strategies to preserve cognitive ability in aging.”
— Veronique Miron, MRC Senior Non-Clinical Fellow and UK Dementia Research Institute group leader at the University of Edinburgh and St. Michael’s Hospital
As an affiliate, we earn on qualifying purchases.
Human Treatment Evidence Is Missing
The study does not establish that reduced NRF2 activity is the cause of cognitive decline in people. The human results come from comparisons between cognitive histories and tissue from a subset of participants, while the experimental manipulation was performed in mice. It remains unclear whether the same biological sequence operates in humans, how common it is, or whether it explains a substantial share of age-related decline.
Nor does the report establish that raising NRF2 activity will preserve cognition in older adults. Medicines acting on the pathway are used for other conditions, but their effects, appropriate dosing and safety for this purpose have not been demonstrated here. The study also does not show that abnormal myelin changes can be reversed once present.
brain health supplements for aging
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Testing NRF2-Based Approaches
The next steps are to test the findings in additional human studies and determine how NRF2 activity changes in oligodendrocytes during aging. Researchers would also need to establish whether interventions that affect the pathway can protect nerve fibers and cognitive function in relevant experimental models.
Any move toward treatment would require clinical trials in older adults, including evidence that a medicine is safe and provides a measurable cognitive benefit. Until then, the findings identify a possible biological target for research rather than a treatment people should seek or use for age-related cognitive decline.
As an affiliate, we earn on qualifying purchases.
Key Questions
What brain cells were studied?
The study focused on oligodendrocytes, cells that produce and maintain myelin, the protective coating around nerve fibers.
What is NRF2, and what did the researchers find?
NRF2 is a protein that regulates genes involved in cellular defense and function. In human tissue, more severe cognitive decline was associated with lower NRF2 levels in oligodendrocytes; reducing NRF2 in mouse oligodendrocytes produced abnormal myelin and nerve-fiber loss.
Does this study show that an existing drug can prevent cognitive decline?
No. The report identifies the NRF2 pathway as a possible research target. It does not show that medicines acting on that pathway prevent or treat age-related cognitive decline in people.
How strong is the evidence that oligodendrocyte changes cause decline in humans?
The human findings show an association between tissue changes and the rate of cognitive decline. Mouse experiments support a causal role in that model, but the study does not establish the same cause-and-effect relationship in humans.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
